$TTNP
TITAN PHARMACEUTICALS INC Stock $ttnp

$ttnp Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-K Financial Statement

#000114420415019881 Filed on March 31, 2015

Income Statement

Concept	2015 Q1	2014 Q4	2013 Q4
Revenue	$911.0K	$912.0K	$911.0K
YoY Change	0.0%	0.11%	-72.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.100M	$570.0K	$620.0K
YoY Change	22.22%	-8.06%	-45.13%
% of Gross Profit
Research & Development	$1.431M	$1.600M	$930.0K
YoY Change	50.79%	72.04%	-63.81%
% of Gross Profit
Depreciation & Amortization	$89.00K	$80.00K	$90.00K
YoY Change	1.14%	-11.11%	800.0%
% of Gross Profit
Operating Expenses	$2.526M	$2.170M	$1.550M
YoY Change	36.91%	40.0%	-58.11%
Operating Profit	-$1.615M
YoY Change	72.91%
Interest Expense	-$3.280M	$770.0K	$430.0K
YoY Change		79.07%	115.0%
% of Operating Profit
Other Income/Expense, Net	-$3.282M	$10.00K	$0.00
YoY Change	277.24%		-100.0%
Pretax Income	-$4.900M	-$470.0K	-$210.0K
YoY Change	172.22%	123.81%	-25.0%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.897M	-$473.0K	-$209.0K
YoY Change	171.45%	126.32%	-25.36%
Net Earnings / Revenue	-537.54%	-51.86%	-22.94%
Basic Earnings Per Share	-$0.24	-$0.02	$0.00
Diluted Earnings Per Share	-$0.24	-$0.06	$0.00
COMMON SHARES
Basic Shares Outstanding	110.3M shares	110.0M shares	82.54M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014 Q4	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.40M	$15.50M	$11.80M
YoY Change	31.37%	31.36%	-34.81%
Cash & Equivalents	$13.42M	$15.47M	$11.80M
Short-Term Investments
Other Short-Term Assets	$300.0K	$100.0K	$200.0K
YoY Change	0.0%	-50.0%	-71.43%
Inventory
Prepaid Expenses
Receivables	$3.500M	$3.968M	$4.818M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.20M	$19.58M	$16.82M
YoY Change	17.77%	16.43%	-28.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.200M	$1.268M	$1.603M
YoY Change	-20.95%	-20.9%	15.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.200M	$1.268M	$1.603M
YoY Change	-20.95%	-20.9%	15.16%
TOTAL ASSETS
Total Short-Term Assets	$17.20M	$19.58M	$16.82M
Total Long-Term Assets	$1.200M	$1.268M	$1.603M
Total Assets	$18.40M	$20.85M	$18.42M
YoY Change	14.12%	13.18%	-25.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.900M	$4.408M	$5.118M
YoY Change	-9.11%	-13.87%	35.86%
Accrued Expenses	$600.0K	$254.0K	$118.0K
YoY Change	337.96%	115.25%	-77.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$5.300M	$6.662M	$10.85M
YoY Change	-42.14%	-38.58%	-49.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$8.900M	$5.600M	$1.800M
YoY Change	229.63%	211.11%	-89.53%
Total Long-Term Liabilities	$8.900M	$5.600M	$0.00
YoY Change	229.63%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.300M	$6.662M	$10.85M
Total Long-Term Liabilities	$8.900M	$5.600M	$0.00
Total Liabilities	$14.20M	$12.24M	$12.66M
YoY Change	19.92%	-3.34%	-73.59%
SHAREHOLDERS EQUITY
Retained Earnings		-$302.8M	-$300.4M
YoY Change		0.8%	-3.13%
Common Stock		$289.2M	$284.5M
YoY Change		1.66%	6.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.200M	$8.611M	$5.760M
YoY Change
Total Liabilities & Shareholders Equity	$18.40M	$20.85M	$18.42M
YoY Change	14.12%	13.18%	-25.79%

Cashflow Statement

Concept	2015 Q1	2014 Q4	2013 Q4
OPERATING ACTIVITIES
Net Income	-$4.897M	-$473.0K	-$209.0K
YoY Change	171.45%	126.32%	-25.36%
Depreciation, Depletion And Amortization	$89.00K	$80.00K	$90.00K
YoY Change	1.14%	-11.11%	800.0%
Cash From Operating Activities	-$2.030M	-$1.580M	-$2.100M
YoY Change	30.13%	-24.76%	-122.34%
INVESTING ACTIVITIES
Capital Expenditures	$7.000K	$0.00	-$20.00K
YoY Change	250.0%	-100.0%	-33.33%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$10.00K	$0.00	-$20.00K
YoY Change		-100.0%	-33.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.00K	9.600M	4.920M
YoY Change		95.12%	33.7%
NET CHANGE
Cash From Operating Activities	-2.030M	-1.580M	-2.100M
Cash From Investing Activities	-10.00K	0.000	-20.00K
Cash From Financing Activities	-10.00K	9.600M	4.920M
Net Change In Cash	-2.050M	8.020M	2.800M
YoY Change	31.41%	186.43%	-78.54%
FREE CASH FLOW
Cash From Operating Activities	-$2.030M	-$1.580M	-$2.100M
Capital Expenditures	$7.000K	$0.00	-$20.00K
Free Cash Flow	-$2.037M	-$1.580M	-$2.080M
YoY Change	30.41%	-24.04%	-122.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	21692000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	284485000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11798000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18423000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15470000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4818000	USD
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1817000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3968000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	289196000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	5760000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	204000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22235000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	145000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	16820000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	19583000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	678000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1603000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1268000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5118000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4408000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	118000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	254000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	293000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	329000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5317000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1671000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10846000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-300417000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6662000	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	5578000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	12663000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	12240000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-302820000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	8611000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20851000	USD
CY2014Q4	us-gaap	Assets Assets	20851000	USD
CY2013Q4	us-gaap	Assets Assets	18423000	USD
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y10M24D
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2581000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	543000	USD
CY2012	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0091	pure
CY2013	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0092	pure
CY2014	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0204	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y1M6D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y5M16D
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.0175	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.0138	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.0165	pure
CY2012	ttnp	Estimated Forfeiture Rates For Options Granted To Management EstimatedForfeitureRatesForOptionsGrantedToManagement	0.31	pure
CY2013	ttnp	Estimated Forfeiture Rates For Options Granted To Management EstimatedForfeitureRatesForOptionsGrantedToManagement	0.31	pure
CY2014	ttnp	Estimated Forfeiture Rates For Options Granted To Management EstimatedForfeitureRatesForOptionsGrantedToManagement	0.31	pure
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1M10D
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P7M24D
CY2012	us-gaap	Licenses Revenue LicensesRevenue	2325000	USD
CY2013	us-gaap	Licenses Revenue LicensesRevenue	9057000	USD
CY2014	us-gaap	Licenses Revenue LicensesRevenue	3646000	USD
CY2012	us-gaap	Royalty Revenue RoyaltyRevenue	4750000	USD
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	1424000	USD
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2012	us-gaap	Revenues Revenues	7117000	USD
CY2013	us-gaap	Revenues Revenues	10481000	USD
CY2014	us-gaap	Revenues Revenues	3646000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10610000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8309000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4075000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4877000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3063000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3046000	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	15487000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	11372000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	7121000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-8370000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-891000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-3475000	USD
CY2012	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4861000	USD
CY2013	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1568000	USD
CY2014	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-183000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10433000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	USD
CY2012	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1766000	USD
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1737000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1083000	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6810000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10602000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1072000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15180000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	9711000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2403000	USD
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66509000	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82099000	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93814000	shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66509000	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82659000	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93832000	shares
CY2013	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	7500000	USD
CY2011Q1	ttnp	Royalty Liability RoyaltyLiability	3000000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12020000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-59000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1022000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3813000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1351000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-710000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	14375000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-9058000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3646000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1830000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9799000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5865000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1154000	USD
CY2011Q4	ttnp	Royalty Liability RoyaltyLiability	5000000	USD
CY2011Q1	ttnp	Percentage Of Aggregate Royalties On Net Sales PercentageOfAggregateRoyaltiesOnNetSales	0.025	pure
CY2011Q1	us-gaap	Royalty Expense RoyaltyExpense	40000000	USD
CY2011Q4	ttnp	Percentage Of Royalty On Net Sales To Third Party PercentageOfRoyaltyOnNetSalesToThirdParty	0.025	pure
CY2011Q4	ttnp	Percentage Of Royalties Above Threshold PercentageOfRoyaltiesAboveThreshold	0.4	pure
CY2011Q4	ttnp	Percentage Of Retain Royalties On Net Sales Above Threshold PercentageOfRetainRoyaltiesOnNetSalesAboveThreshold	0.6	pure
CY2013Q1	ttnp	Gains Losses On Extinguishment Of Royalty Liability GainsLossesOnExtinguishmentOfRoyaltyLiability	9000000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-15180000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	9711000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-2403000	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	107000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	353000	USD
CY2012	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1860000	USD
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2012	ttnp	Noncash Gain On Termination Of Royalty Purchase Agreement NoncashGainOnTerminationOfRoyaltyPurchaseAgreement	0	USD
CY2013	ttnp	Noncash Gain On Termination Of Royalty Purchase Agreement NoncashGainOnTerminationOfRoyaltyPurchaseAgreement	8962000	USD
CY2014	ttnp	Noncash Gain On Termination Of Royalty Purchase Agreement NoncashGainOnTerminationOfRoyaltyPurchaseAgreement	0	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	2581000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	678000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	543000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	926000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	172000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-850000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-149000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-483000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	318000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1154000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-318000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-18000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	113000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2012	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4897000	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1275000	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2012	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	393000	USD
CY2013	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2500000	USD
CY2014	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9555000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	12696000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6304000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3672000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5406000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18102000	USD
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 12.2pt"> <strong><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 12.2pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014	dei	Entity Registrant Name EntityRegistrantName	TITAN PHARMACEUTICALS INC
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0000910267
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q2	dei	Entity Public Float EntityPublicFloat	60700000	USD
CY2014	dei	Trading Symbol TradingSymbol	TTNP
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	110327707	shares
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-15180000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	7974000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3486000	USD
CY2012	ttnp	Incremental Common Shares Attributable To Assumed Exercise Of Options IncrementalCommonSharesAttributableToAssumedExerciseOfOptions	0	shares
CY2013	ttnp	Incremental Common Shares Attributable To Assumed Exercise Of Options IncrementalCommonSharesAttributableToAssumedExerciseOfOptions	493000	shares
CY2014	ttnp	Incremental Common Shares Attributable To Assumed Exercise Of Options IncrementalCommonSharesAttributableToAssumedExerciseOfOptions	18000	shares
CY2012	ttnp	Incremental Common Shares Attributable To Assumed Exercise Of Warrants IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants	0	shares
CY2013	ttnp	Incremental Common Shares Attributable To Assumed Exercise Of Warrants IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants	67000	shares
CY2014	ttnp	Incremental Common Shares Attributable To Assumed Exercise Of Warrants IncrementalCommonSharesAttributableToAssumedExerciseOfWarrants	0	shares
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7224000	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3303000	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9227000	shares
CY2012Q4	ttnp	Class Of Warrants Fair Value Disclosure ClassOfWarrantsFairValueDisclosure	8240000	USD
CY2013Q4	ttnp	Class Of Warrants Fair Value Disclosure ClassOfWarrantsFairValueDisclosure	1817000	USD
CY2013	ttnp	Warrants Issued WarrantsIssued	0	USD
CY2014	ttnp	Warrants Issued WarrantsIssued	4844000	USD
CY2013	ttnp	Excercise Of Warrants ExcerciseOfWarrants	4686000	USD
CY2014	ttnp	Excercise Of Warrants ExcerciseOfWarrants	0	USD
CY2013	ttnp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	-1737000	USD
CY2014	ttnp	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	-1083000	USD
CY2014Q4	ttnp	Class Of Warrants Fair Value Disclosure ClassOfWarrantsFairValueDisclosure	5578000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	15200000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	9700000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2400000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	106000	USD
CY2013Q1	us-gaap	Revenues Revenues	5174000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-1145000	USD
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	209000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	211000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	317000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4157000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4175000	USD
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	203000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	210000	USD
CY2012	ttnp	Expense Incurred Under Research And License Agreements ExpenseIncurredUnderResearchAndLicenseAgreements	3000	USD
CY2013	ttnp	Expense Incurred Under Research And License Agreements ExpenseIncurredUnderResearchAndLicenseAgreements	3000	USD
CY2014	ttnp	Expense Incurred Under Research And License Agreements ExpenseIncurredUnderResearchAndLicenseAgreements	3000	USD
CY2014Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	0	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	5064000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-842000	USD
CY2014Q1	us-gaap	Revenues Revenues	911000	USD
CY2013Q2	us-gaap	Revenues Revenues	2198000	USD
CY2014Q2	us-gaap	Revenues Revenues	911000	USD
CY2013Q3	us-gaap	Revenues Revenues	2198000	USD
CY2014Q3	us-gaap	Revenues Revenues	911000	USD
CY2013Q4	us-gaap	Revenues Revenues	911000	USD
CY2014Q4	us-gaap	Revenues Revenues	912000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	6001000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-1804000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	716000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-209000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-473000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2012	ttnp	Income Tax Reconciliation Noncash Gain From Termination Of Royalty Purchase Agreement IncomeTaxReconciliationNoncashGainFromTerminationOfRoyaltyPurchaseAgreement	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	105926000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5134000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3301000	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-839000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	85912000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	88086000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	13481000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	13645000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3962000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3529000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2116000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	666000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	105471000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	105926000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	105471000	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-234000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	213000	USD
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	592000	USD
CY2012	ttnp	Income Tax Reconciliation Book Gains Losses Not Currently Benefited IncomeTaxReconciliationBookGainsLossesNotCurrentlyBenefited	3120000	USD
CY2013	ttnp	Income Tax Reconciliation Book Gains Losses Not Currently Benefited IncomeTaxReconciliationBookGainsLossesNotCurrentlyBenefited	1656000	USD
CY2014	ttnp	Income Tax Reconciliation Book Gains Losses Not Currently Benefited IncomeTaxReconciliationBookGainsLossesNotCurrentlyBenefited	454000	USD
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1901000	USD
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-476000	USD
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	235000	USD
CY2012	ttnp	Income Tax Reconciliationdisallowed Interest Expense IncomeTaxReconciliationdisallowedInterestExpense	1363000	USD
CY2013	ttnp	Income Tax Reconciliationdisallowed Interest Expense IncomeTaxReconciliationdisallowedInterestExpense	160000	USD
CY2014	ttnp	Income Tax Reconciliationdisallowed Interest Expense IncomeTaxReconciliationdisallowedInterestExpense	0	USD
CY2012	ttnp	Income Tax Reconciliation Income From Debt Restructuring IncomeTaxReconciliationIncomeFromDebtRestructuring	-1615000	USD
CY2013	ttnp	Income Tax Reconciliation Income From Debt Restructuring IncomeTaxReconciliationIncomeFromDebtRestructuring	0	USD
CY2014	ttnp	Income Tax Reconciliation Income From Debt Restructuring IncomeTaxReconciliationIncomeFromDebtRestructuring	0	USD
CY2012	ttnp	Income Tax Reconciliation Revaluation Of Warrant Liability IncomeTaxReconciliationRevaluationOfWarrantLiability	600000	USD
CY2013	ttnp	Income Tax Reconciliation Revaluation Of Warrant Liability IncomeTaxReconciliationRevaluationOfWarrantLiability	-591000	USD
CY2014	ttnp	Income Tax Reconciliation Revaluation Of Warrant Liability IncomeTaxReconciliationRevaluationOfWarrantLiability	-346000	USD
CY2012	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	583000	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	97000	USD
CY2013	ttnp	Income Tax Reconciliation Noncash Gain From Termination Of Royalty Purchase Agreement IncomeTaxReconciliationNoncashGainFromTerminationOfRoyaltyPurchaseAgreement	-3047000	USD
CY2014	ttnp	Income Tax Reconciliation Noncash Gain From Termination Of Royalty Purchase Agreement IncomeTaxReconciliationNoncashGainFromTerminationOfRoyaltyPurchaseAgreement	0	USD
CY2012	ttnp	Income Tax Reconciliation Noncash Gain On Settlement Of Longterm Debt IncomeTaxReconciliationNoncashGainOnSettlementOfLongtermDebt	0	USD
CY2013	ttnp	Income Tax Reconciliation Noncash Gain On Settlement Of Longterm Debt IncomeTaxReconciliationNoncashGainOnSettlementOfLongtermDebt	632000	USD
CY2014	ttnp	Income Tax Reconciliation Noncash Gain On Settlement Of Longterm Debt IncomeTaxReconciliationNoncashGainOnSettlementOfLongtermDebt	0	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1000	USD
CY2014	ttnp	Tax Credit Research Generated During Period TaxCreditResearchGeneratedDuringPeriod	340000	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3100000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1700000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	500000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2012	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-347000	USD
CY2013	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	0	USD
CY2014	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	0	USD
CY2012	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	417000	USD
CY2013	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-340000	USD
CY2014	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	172000	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012	us-gaap	Interest Paid InterestPaid	2576000	USD
CY2013	us-gaap	Interest Paid InterestPaid	1568000	USD
CY2014	us-gaap	Interest Paid InterestPaid	0	USD
CY2012	ttnp	Settlement Of Longterm Debt SettlementOfLongtermDebt	0	USD
CY2013	ttnp	Settlement Of Longterm Debt SettlementOfLongtermDebt	7500000	USD
CY2014	ttnp	Settlement Of Longterm Debt SettlementOfLongtermDebt	0	USD
CY2012	ttnp	Fair Value Of Warrants FairValueOfWarrants	0	USD
CY2013	ttnp	Fair Value Of Warrants FairValueOfWarrants	4686000	USD
CY2014	ttnp	Fair Value Of Warrants FairValueOfWarrants	0	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88794222	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	109997533	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88794222	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109997533	shares
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-20079000	USD
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21789000	shares
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4653000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4925000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4747000	USD
CY2012	ttnp	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	4897000	USD
CY2013	ttnp	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	13461000	USD
CY2012	us-gaap	Revenue From Grants RevenueFromGrants	42000	USD
CY2013	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2014	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-36000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2581000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	678000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	543000	USD
CY2014	ttnp	Notional Liquidation Damages NotionalLiquidationDamages	2500000	USD
CY2014	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	0.45
CY2014	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	3.13
CY2014Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6620000	shares
CY2014	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y1M20D
CY2014Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1.23
CY2014Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	6495000	shares
CY2014Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	1.24
CY2014Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12388000	shares
CY2014Q4	ttnp	Underwritten Public Offering Number Of Units Issued UnderwrittenPublicOfferingNumberOfUnitsIssued	21000000	shares
CY2014Q4	ttnp	Underwritten Public Offering Offering Price Of Units Issued UnderwrittenPublicOfferingOfferingPriceOfUnitsIssued	0.50
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2014Q4	ttnp	Underwritten Public Offering Description Of Units Issued UnderwrittenPublicOfferingDescriptionOfUnitsIssued	each unit consisting of one share of common stock and 0.75 of a warrant, each full warrant to purchase one share of common stock at an exercise price of $0.60 per share.
CY2014Q4	ttnp	Underwritten Public Offering Proceeds From Units Issued UnderwrittenPublicOfferingProceedsFromUnitsIssued	9600000	USD
CY2012	ttnp	Share Based Compensation Expense Impact On Basic Earnings Per Share ShareBasedCompensationExpenseImpactOnBasicEarningsPerShare	-0.04
CY2013	ttnp	Share Based Compensation Expense Impact On Basic Earnings Per Share ShareBasedCompensationExpenseImpactOnBasicEarningsPerShare	-0.01
CY2014	ttnp	Share Based Compensation Expense Impact On Basic Earnings Per Share ShareBasedCompensationExpenseImpactOnBasicEarningsPerShare	-0.01
CY2012	ttnp	Share Based Compensation Expense Impact On Diluted Earnings Per Share ShareBasedCompensationExpenseImpactOnDilutedEarningsPerShare	-0.04
CY2013	ttnp	Share Based Compensation Expense Impact On Diluted Earnings Per Share ShareBasedCompensationExpenseImpactOnDilutedEarningsPerShare	-0.01
CY2014	ttnp	Share Based Compensation Expense Impact On Diluted Earnings Per Share ShareBasedCompensationExpenseImpactOnDilutedEarningsPerShare	-0.01
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.09
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.64
CY2012	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7516000	USD
CY2013	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4925000	USD
CY2014	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9591000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-23128000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	113000	USD
CY2012	ttnp	Stock Issued From Vesting Of Restricted Stock StockIssuedFromVestingOfRestrictedStock	0	USD
CY2013	ttnp	Stock Issued From Vesting Of Restricted Stock StockIssuedFromVestingOfRestrictedStock	0	USD
CY2014	ttnp	Stock Issued From Vesting Of Restricted Stock StockIssuedFromVestingOfRestrictedStock	36000	USD

Files In Submission

Name	View Source	Status
0001144204-15-019881-index-headers.html	Edgar Link	pending
0001144204-15-019881-index.html	Edgar Link	pending
0001144204-15-019881.txt	Edgar Link	pending
0001144204-15-019881-xbrl.zip	Edgar Link	pending
chart1.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ttnp-20141231.xml	Edgar Link	completed
ttnp-20141231.xsd	Edgar Link	pending
ttnp-20141231_cal.xml	Edgar Link	unprocessable
ttnp-20141231_def.xml	Edgar Link	unprocessable
ttnp-20141231_lab.xml	Edgar Link	unprocessable
ttnp-20141231_pre.xml	Edgar Link	unprocessable
v404713_10k.htm	Edgar Link	pending
v404713_ex23-1.htm	Edgar Link	pending
v404713_ex31-1.htm	Edgar Link	pending
v404713_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TTNP
TITAN PHARMACEUTICALS INC Stock $ttnp

2015 Q1 Form 10-K Financial Statement

#000114420415019881 Filed on March 31, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTNP TITAN PHARMACEUTICALS INC Stock $ttnp

2015 Q1 Form 10-K Financial Statement

#000114420415019881 Filed on March 31, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTNP
TITAN PHARMACEUTICALS INC Stock $ttnp